Treato Finds Demand Will be High for Heart Failure Drug Entresto

NEW YORK, Sept. 9, 2015 /PRNewswire/ -- Consumer demand for Entresto, a a potential blockbuster heart failure drug manufactured by Novartis, will be high according to a data analysis released today by consumer healthcare insights company Treato. Through analyzing more than 128,000 online discussions about Entresto and statins, Treato discovered that consumer conversations about Entresto have grown 1,400 percent the since the FDA fast-tracked its approval in July.

Entresto was approved for the treatment of heart failure after it was shown in clinical trials to reduce hospitalizations among patients who suffer from chronic heart failure. Consumers are eager to obtain the drug as 97 percent of their online discussions about Entresto mention heart failure.  It's clear that consumers understand the tremendous effect Entresto could have on people suffering from heart disease, as more than 30 percent of online conversations mention hospitalization (most people who are hospitalized for heart failure are readmitted soon after). However, the ability to afford the twice-daily drug is a concern to consumers, as more than 15 percent of all online conversations about Entresto mentioned cost.

Before Entresto's approval, statins were the dominant class of drugs used to prevent heart disease through the lowering of cholesterol levels.  A data analysis of statins revealed that Pfizer's Lipitor dominates online conversations.  Lipitor is discussed three times more frequently than simvastatin, the generic for Merck's Zocor, which is the second most frequently discussed statin online.  However, Lipitor's hold on the market seems to be waning as consumers are frequently discussing switching to another statin. Consumers discuss switching from Lipitor to Crestor four times more frequently than the reverse. 

"Analyzing online conversations to gauge consumer interest in a new form of therapy is a key resource in understanding an opportunity for a new drug in the market," says Ido Hadari, CEO of Treato.  "As seen with Entresto, consumers with chronic heart failure are being very vocal about their desire for another line of therapy to treat their condition.  It's clear their advanced medical needs are not being met by the drugs currently on the market."

Find more information about Entresto drug reviews and Treato's Entresto data analysis.

About Treato:

Treato™, the leading source of real health insights from millions of real health consumers, uses patented analytics and big data technology to turn billions of disparate online conversations into meaningful social intelligence.  With two billion posts analyzed and continuously expanding, Treato has partnered with 8 out of the world's top 10 pharma companies as well as numerous other multi-national pharmaceutical companies and healthcare organizations.   Treato.com, its consumer website, helps millions of visitors each month.

Treato is privately held with offices in Israel, New York and Princeton, NJ. Investors include Reed Elsevier Ventures, OrbiMed Partners and New Leaf Venture Partners, among others. For more information please visit http://treato.com 

Allyson Noonan
Media Relations Manager
+1(858)245-7256
[email protected]

Photo - http://photos.prnewswire.com/prnh/20150909/264765-INFO

SOURCE Treato